Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.700903
Title: Preclinical evaluation of Meriva (a formulation of curcumin) as a putative agent for chemoprevention of lung cancer
Author: Mahale, Jagdish
ISNI:       0000 0004 5989 3990
Awarding Body: University of Leicester
Current Institution: University of Leicester
Date of Award: 2016
Availability of Full Text:
Access from EThOS:
Access from Institution:
Abstract:
Curcumin, a naturally occurring dietary polyphenol, has been investigated for several years for its role in chemoprevention of cancer. There are emerging evidences that curcumin may have a potential role in prevention and treatment of lung cancer. Curcumin in its natural form is poorly absorbed, extensively metabolised and rapidly excreted. Meriva, a phospholipid formulation of curcumin, promises to enhance its bioavaibility. The work described in this thesis investigates whether Meriva offers pharmacokinetic advantage over unformulated curcumin, elucidate a possible mechanism of action for curcumin and determine efficacy of Meriva in vivo using xenograft model of lung cancer. Meriva offered superior curcumin and curcumin metabolites levels in mice plasma and lungs at two different dose levels (high and low). The levels were 5-16 fold higher for Meriva as compared to unformulated curcumin. A HPLC-UV method developed and validated for simultaneous quantification of curcumin and metabolites was found to reliable and reproducible. In vitro, a 3D organotypic model was used to demonstrate important role stromal components, namely fibroblasts, play in cell invasion and metastasis. Curcumin treatment of organotypic cultures significantly inhibited tumour cell invasion. Curcumin also modulated a number of key proteins in HGF/MET signalling axis. Nude mice were administered either control diet or diet supplemented with 0.226% w/w Meriva one week after A549:MRC5 (1:5) cell inoculation. Meriva significantly inhibited tumour growth versus control (p<0.05). The expression of p53, Ki-67 and cleaved caspase-3 which were significantly altered following Meriva intervention. These results together provide evidence that Meriva at a clinical relevant dose regime may be investigated in prevention and treatment of lung cancer.
Supervisor: Bown, Karen ; Howells, Lynne Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.700903  DOI: Not available
Share: